Pharmacologic issues of antiretroviral agents and immunosuppressive regimens in HIV-infected solid organ transplant recipients

Infectious Disease Clinics of North America

Volumn 27, Issue 2, 2013, Pages 473-486

  Primeggia, Jennifer ^a   Timpone, Joseph G ^a   Kumar, Princy N ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug interactions; HIV; Immunosuppression; Organ transplantation

Indexed keywords

ABACAVIR; ATAZANAVIR; AZATHIOPRINE; CYCLOSPORIN; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; PREDNISONE; PROTEINASE INHIBITOR; RAPAMYCIN; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TACROLIMUS; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ADRENAL CORTEX INSUFFICIENCY; BONE MARROW TOXICITY; COMA; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DELIRIUM; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEART VENTRICLE HYPERTROPHY; HEMOLYTIC UREMIC SYNDROME; HIRSUTISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; INTERSTITIAL LUNG DISEASE; LACTIC ACIDOSIS; LEUKOPENIA; LIVER TOXICITY; LIVER TRANSPLANTATION; MENTAL INSTABILITY; MULTIPLE ORGAN FAILURE; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORGAN TRANSPLANTATION; PARESTHESIA; PERIPHERAL EDEMA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POTASSIUM EXCRETION; PURE RED CELL ANEMIA; RECIPIENT; REVIEW; RISK FACTOR; SIDE EFFECT; SODIUM RETENTION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VOMITING; WATER RETENTION;

ANTI-RETROVIRAL AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 84878221903     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2013.02.011     Document Type: Review

References (52)

1. Weber R., Sabin C.A., Friss-Moller N., et al. Liver-related deaths in persons infected with human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632-1641.
2. Salmon-Ceron D., Lewden C., Morlat P., et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005, 42:799-805.
3. Moodie E.E., Pant Pai N., Klein M.B. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/Hepatitis C co-infected cohorts. PLoS One 2009, 4:e4517. 10.1371/journal.pone.0004517.
4. Hester E.K. HIV medications: an update and review of metabolic complications. Nutr Clin Pract 2012, 27:51-64.
5. Roline G., Schmid H., Fischereder M., et al. HIV-associated renal disease and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006, 42:1488-1495.
6. Gupta S.K., Eustace J.A., Winston J.A., et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Disease Society of America. Clin Infect Dis 2005, 40:1559-1585.
7. Stock P.G., Barin B., Murphy B., et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010, 363:2004-2014.
8. Mindikoglu A.L., Regev A., Magder L.S. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008, 85:359-368.
9. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004, 351:2715-2729.
10. Tedesco D., Haragsim L. Cyclosporine: a review. J Transplant 2012, 2012:230386. 7. 10.1155/2012/230386.
11. Roland M.E., Stock P.G. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006, 26:273-284.
12. Nelson M.R., Katlama C., Montaner J.S., et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infections in adults: the first 4 years. AIDS 2007, 21:1273-1281.
13. Guitard J., Rostaing L., Kamar N. New-onset diabetes and nephropathy after renal transplantation. Contrib Nephrol 2011, 170:247-255.
14. Marti H.P., Frey F.J. Nephrotoxicity of rapamycin: an emerging problem in clinical medicine. Nephrol Dial Transplant 2005, 20:13-15.
15. Chapman J.R. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011, 11:693-697.
16. Castellano C, Williams W, Kepler TB, et al. Clinical predictors of tenofovir-associated nephrotoxicity in HIV-1-infected patients. Paper presented at: XVII International AIDS Conference [abstract WEAB0104]. Mexico City (Mexico), August 3-8, 2008.
17. Margolis D., Heredia A., Gaywee J., et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999, 21:362-370.
18. Antoniades C., Macdonald C., Knisely A., et al. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. Liver Transpl 2004, 10:699-702.
19. Marfo K., Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplant Proc 2009, 41:3796-3799.
20. Frassetto L., Baluom M., Jacobeson W., et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005, 80:13-17.
21. Stock P.G., Roland M.E., Carlson L., et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003, 76:370-375.
22. Frassetto L.A., Browne M., Cheng A., et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007, 7:2816-2820.
23. Teicher E., Vincent I., Bonhomme-Faivre L., et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS CH-08 study. Clin Pharmacokinet 2007, 46:941-952.
24. Mouly S., Lown K.S., Kornhauser D., et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002, 72:1-9.
25. Kakuda T.N., Scholler-Gyure M., Hoetelmans R.M. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011, 50:25-39.
26. Di Biagio A., Rosso R., Siccardi M., et al. Lack of interaction between raltegravir and cyclosporine in an HIV-infected liver transplant recipient. J Antimicrob Chemother 2009, 64:874-875.
27. Edurant (rilpivirine) tablets [package insert]. Raritan, NJ: Tibotec Pharmaceuticals; 2011.
28. Guaraldi G., Cocchi S., Motta A., et al. Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplant. Am J Transplant 2009, 9:2429-2434.
29. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2011, Department of Health and Human Services, p. 1-166. Available at:, Accessed August 1, 2011. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
30. Vogel M., Voigt E., Michaelis H.C., et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004, 20:939-944.
31. Jain A.B., Venkataramanan R., Eghtesad B., et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003, 9:954-960.
32. Schonder K.S., Schullo M.A., Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003, 37:1793-1796.
33. Barau C., Blouin P., Creput C., et al. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. Fundam Clin Pharmacol 2009, 23:423-425.
34. Meretz D., Battegay M., Marzolini C., et al. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. Am J Kidney Dis 2009, 54:e1-e4.
35. Frassetto L., Thai T., Aggarwal A.M., et al. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet 2003, 18:114-120.
36. Jain A.K., Venkataramanan R., Fridell J.A., et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl 2002, 8:838-840.
37. Perloff E.S., Duan S.X., Skolnik P.R., et al. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005, 33:764-770.
38. Tsaperas D.S., Webber A.B., Aull M.J., et al. Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient. Am J Health Syst Pharm 2011, 15:138-142.
39. Reyataz (atazanavir sulfate) capsules [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.
40. Prednisone [package insert]. Columbus, OH: Roxane Laboratories, Inc; 2009.
41. Dort K., Padia S., Wispelwey B., et al. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther 2009, 6:10.
42. Herold M.A., Gunthard H.F. Cushing syndrome after steroid-infiltration in two HIV-patients with antiretroviral therapy. Praxis 2010, 99:863-865.
43. Molloy A., Matheson N.J., Meyer P.A., et al. Cushing's syndrome and adrenal axis suppression in a patient treated with ritonavir and corticosteroid eye drops. AIDS 2011, 25:1337-1339.
44. Busse K.H., Formentini E., Alfar R., et al. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals. J Acquir Immune Defic Syndr 2008, 15:561-566.
45. Tricot L., Teicher E., Peytavin G., et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009, 9:1946-1952.
46. Miro J.M., Ricart M.J., Trullas J.C., et al. Simultaneous pancreas-kidney transplantation in HIV-infected patients: a case report and literature review. Transplant Proc 2010, 42:3887-3891.
47. Moreno A., Barcena R., Quereda C., et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS 2008, 22:547-548.
48. Stribilid (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets [package insert]. Foster City, CA: Gilead Sciences, Inc; 2012.
49. Selzentry (maraviroc) tablets [package insert]. Freiburg, Germany: Pfizer Manufacturing Deutschland GmbH; 2010.
50. Heidenhain C., Pulh G., Moench C., et al. Chemokine receptor 5Δ32 mutation reduces the risk of acute rejection in liver transplantation. Ann Transplant 2009, 14:36-44.
51. Reshef R., Luger S.M., Hexner E.O., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012, 367:135-145.
52. Gilliam B.L., Heredia A., Devico A., et al. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS 2007, 21:2108-2110.